Abstract
Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1021-1025 |
| Number of pages | 5 |
| Journal | Stem Cell Reports |
| Volume | 11 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 13 2018 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Genetics
- Developmental Biology
- Cell Biology
Cite this
Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies : ISSCR 2018 Annual Meeting Focus Session Report. / Sugarman, Jeremy; Barker, Roger A.; Kerridge, Ian; Lysaght, Tamra; Pellegrini, Graziella; Sipp, Douglas; Tanner, Claire.
In: Stem Cell Reports, Vol. 11, No. 5, 13.11.2018, p. 1021-1025.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies
T2 - ISSCR 2018 Annual Meeting Focus Session Report
AU - Sugarman, Jeremy
AU - Barker, Roger A.
AU - Kerridge, Ian
AU - Lysaght, Tamra
AU - Pellegrini, Graziella
AU - Sipp, Douglas
AU - Tanner, Claire
PY - 2018/11/13
Y1 - 2018/11/13
N2 - Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.
AB - Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.
UR - http://www.scopus.com/inward/record.url?scp=85055877161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055877161&partnerID=8YFLogxK
U2 - 10.1016/j.stemcr.2018.10.020
DO - 10.1016/j.stemcr.2018.10.020
M3 - Article
C2 - 30428384
AN - SCOPUS:85055877161
VL - 11
SP - 1021
EP - 1025
JO - Stem Cell Reports
JF - Stem Cell Reports
SN - 2213-6711
IS - 5
ER -